Astellas Pharma Inc. (ALPMY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Naoki Okamura BSc | President, CEO & Director | 1.96M | -- | 1962 |
| Mr. Atsushi Kitamura | Senior Executive Officer & CFO | -- | -- | -- |
| Nobue Yasuda | General Manager of Finance & Accounting Department | -- | -- | -- |
| Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer | -- | -- | -- |
| Ms. Catherine B. Levitt | General Counsel | -- | -- | -- |
| Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director | -- | -- | 1967 |
| Mr. Stig Ogata | Vice President of Corporate Communications | -- | -- | -- |
| Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance | -- | -- | -- |
| Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | -- | -- | -- |
| Jun Kono | Senior Executive Officer & Head of Japan Commercial | -- | -- | -- |
Astellas Pharma Inc.
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - General
- Full Time Employees:?
- 14,754
Description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
October 30, 2024 at 6:00 AM UTC
Astellas Pharma Inc. Earnings Date
Recent Events
March 27, 2024 at 12:00 AM UTC
Ex-Dividend Date
December 17, 2019 at 12:00 AM UTC
Dividend Date